Skip to main content

Table 1 Clinical characteristics of 148 patients by the LMR level at diagnosis

From: The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma

CharacteristicNo. (%)Low LMR group
LMR ≤ 2.7
High LMR group
LMR > 2.7
Gender
 Male91 (61.5)22 (14.9)69 (46.6)
 Female57 (38.5)15 (10.1)42 (28.4)
Age (year)
 > 6018 (12.2)6 (4.1)12 (8.1)
 ≤ 60130 (87.8)31 (20.9)99 (66.9)
B symptoms
 Absent65 (43.9)14 (9.5)51 (34.5)
 Present83 (56.1)23 (15.5)60 (40.5)
Lugano stage
 I–II2119 (80.4)22 (14.9)97 (65.5)
 III–IV29 (19.6)15 (10.1)14 (9.5)
ECOG PS
 < 2143 (96.6)35 (23.6)108 (73.0)
 ≥ 25 (3.4)2 (1.4)3 (2.0)
LDH
 Normal107 (72.3)23 (15.5)84 (56.8)
 Abnormal41 (27.7)14 (9.5)27 (18.2)
IPI score
 0–2137 (92.6)32 (21.6)105 (70.9)
 3–511 (7.4)5 (3.4)6 (4.1)
Distant metastasis
 Yes97 (65.5)22 (14.9)65 (43.9)
 No51 (35.5)15 (10.1)36 (24.3)
Chemotherapy regimen
 DIE-L59 (39.9)45 (30.4)14 (9.5)
 GDP-L37 (25.0)28 (18.9)9 (6.1)
 CHOP-L22 (14.9)17 (11.5)5 (3.4)
 SMILE19 (12.8)13 (8.8)6 (4.1)
 P-Gemox6 (4.1)4 (2.7)2 (1.4)
  1. DIE-L ifosfamide, etoposide, dexamethasone, and l-asparaginase, GDP-L gemcitabine, dexamethasone, cisplatin, and l-asparaginase, CHOP-L cyclophosphamide, doxorubicin, vincristine, prednisolone, and l-asparaginase, SMILE dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide, P-Gemox gemcitabine, oxaliplatin, and pegaspargase